5% Human Normal Immunoglobulin (Hemarus Therapeutics)

N/A

Report date: 2022/01/24 16:19:08

Base Information

Drug Name5% Human Normal Immunoglobulin (Hemarus Therapeutics)
Drug Alias NameImmuglo
ClassificationBiologics
Mechanisms of ActionImmunoglobulin replacements
TargetsImmunoglobulin
Therapy Area/IndicationsImmunologic Deficiency SyndromesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[7] 
Global Approved IndicationsImmunologic Deficiency SyndromesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[7] 
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved Date2015/08/01
Country/TerritoryN/A
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaN/A
Originator CompaniesHemarus Therapeutics
China Registration ClassN/A

Develop Information

Active CompaniesHemarus Therapeutics
Inactive CompaniesN/A
Active IndicationsImmunologic Deficiency SyndromesAgammaglobulinemiaPurpura, Thrombocytopenic, Idiopathic +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeJ06BA02
Related LinksN/A